Golgi phosphoprotein 3 promotes the proliferation of gallbladder carcinoma cells via regulation of the NLRP3 inflammasome

ZHENCHENG ZHU1,2*, QINGZHOU ZHU1,2*, DONGPING CAI3, LIANG CHEN4, WEIXUAN XIE2, YANG BAI2 and KUNLUN LUO1,2

1Anhui Medical University, Hefei, Anhui 230032; Departments of 2Hepatobiliary Surgery, 3Laboratory and 4Cardiology, The 904th Hospital of Joint Logistic Support Force of PLA, Wuxi, Jiangsu 214044, P.R. China

Received January 18, 2021; Accepted April 2, 2021

DOI: 10.3892/or.2021.8064

Correspondence to: Professor Kunlun Luo, Department of Hepatobiliary Surgery, The 904th Hospital of Joint Logistic Support Force of PLA, 101 Xingyuan North Road, Wuxi, Jiangsu 214044, P.R. China
E-mail: lkl197041@163.com

*Contributed equally

Key words: gallbladder carcinoma, molecular mechanism, inflammation, golgi phosphoprotein 3, nucleotide-binding domain leucine-rich repeat and pyrin domain containing receptor 3

Abstract. Golgi phosphoprotein 3 (GOLPH3) has been demonstrated to promote tumor progression in various gastrointestinal malignancies. However, its effects in gallbladder carcinoma (GBC) remain unknown. In the present study, the expression levels of GOLPH3 and nucleotide-binding domain leucine-rich repeat and pyrin domain containing receptor 3 (NLRP3) in human GBC tissues were detected by immunohistochemistry, and the clinical data and survival of these patients were analyzed. Next, whether GOLPH3 could affect tumor proliferation via regulation of the NLRP3 inflammasome was investigated in vitro. The results demonstrated that GOLPH3 could promote GBC cell proliferation, and that it regulated protein expression levels of NLRP3, as well as Caspase-1 P10. Conversely, knockdown of NLRP3 reversed the effects of GOLPH3 overexpression on GBC cell proliferation. GOLPH3 and NLRP3 expression levels were found to be upregulated in GBC tissues and their expression was positively correlated. The expression of GOLPH3 and NLRP3 was associated with the expression of the proliferative marker Ki-67 in tissues, and associated with poor survival, tumor stage, degree of differentiation, depth of invasion, carbohydrate antigen 19-9 and C-reactive protein levels in patients with GBC. In summary, these results indicate that GOLPH3 promotes GBC cell proliferation via a NLRP3/Caspase-1 pathway. GOLPH3 and NLRP3 participate in the process of human GBC growth and may serve as a potential therapeutic targets.

Introduction

Gallbladder carcinoma (GBC) is a highly malignant tumor of the biliary system with a median survival time of only 6 months (1-3). The primary pathological type of GBC observed in patients is adenocarcinoma. The effects of current chemotherapeutic regimens are not sufficient for GBC due to the lack of effective drugs, making it particularly difficult to control the mortality rate of GBC (3,4). Due to the close relationship between inflammation and GBC, investigation of inflammatory-related molecular mechanisms may highlight novel specific targets for the treatment of GBC (4).

Golgi phosphoprotein 3 (GOLPH3) is a component of the trans Golgi network (TGN) (5-7). Physiologically, GOLPH3 stabilizes the Golgi structure and promotes the sprouting of Golgi vesicles through binding with phosphatidylinositol 4-phosphate [PtdIns(4)P] and myosin18A (5,8,9). Excessive activation of GOLPH3 induces the breakdown of the Golgi apparatus (8-10). Recently, several studies have reported that GOLPH3 serves an important role in the progression of several types of cancer, such as hepatocellular carcinoma, gastric adenocarcinoma and lung adenocarcinoma (11-14). In addition, GOLPH3 is involved in the process of chemotherapeutic resistance, further highlighting its close relationship with tumor progression (8,15). It has been reported that GOLPH3 promotes tumor growth via several signaling pathways, including the PI3K/AKT/mTOR pathway (14-17). However, the role and mechanism of GOLPH3 in GBC remain unknown.

Nucleotide-binding domain leucine-rich repeat (NLR) and pyrin domain containing receptor 3 (NLRP3) comprise the NLRP3 inflammasomes together with apoptosis associated speck like protein and pro-caspase-1 (18,19). Physiological levels of NLRP3 activation protects the body's inflammatory immune system via activation of Caspase-1, whereas uncontrolled activation will lead to dysregulated inflammation, autoimmune diseases, neurodegenerative diseases, and even malignant tumors (20-24). Recently, a number of studies have reported that the overactivation of NLRP3 is closely associated with the progression of several malignant tumors (24-27). To date, there are numerous studies on the downstream effects of NLRP3 (22-25). There is evidence that the NLRP3/Caspase-1 pathway can promote the occurrence and progression of adenocarcinoma, and IL-1β, an important member of the NLRP3...
inflammation, has been found to be closely related with the proliferation of GBC (25,28). Nevertheless, the specific molecular mechanisms by which NLRP3 is pathophysiologically activated remains unknown.

Thus, both GOLPH3 and NLRP3 are associated with tumor progression. However, the relationship between GOLPH3 and NLRP3 in tumorigenesis and progression remains unclear. Evidence has shown that excessive activation of GOLPH3 can cause the fragmentation of the Golgi apparatus, and the fragmentation of the TGN is closely associated with the activation of NLRP3 (8,10,21). In the present study, the expression levels of GOLPH3 and NLRP3 in human GBC tissues were detected via immunohistochemistry, and the clinical data and survival of these patients were analyzed. Then, it was tested whether GOLPH3 can affect tumor proliferation via regulation of the NLRP3 inflammasome in vitro. Through these experiments, the aim was to find out whether GOLPH3 is an upstream regulator of the NLRP3/Caspase-1 pathway in the proliferation of GBC cells.

Materials and methods

Cell culture. The human GBC-SD cell line was purchased from Guangzhou Cellcook Biotech Co., Ltd. Cells were grown in RPMI-1640 medium (Hyclone; Cytiva) supplemented with 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) in a humidified incubator with 5% CO2 at 37˚C.

Small interfering (si)RNA and plasmid transfection. Knocking down of GOLPH3 and NLRP3 was performed using specific siRNA Oligos (Guangzhou RiboBio Co., Ltd.). The sequences of the siRNAs were as follows: si-negative control (NC) sense, 5'-UUCUUCCGAAAGUGACGU-3' and anti-sense, 5'-ACGUGACCGUUCGGAGA-3'; si-NLRP3 (3xFlag-SiR) sense, 5'-GGCAGACCAUGUGGAUCATT-3' and anti-sense, 5'-UGAUUAGUACACUGUCUGGTC-3'; si-GOLPH3-A (GOLPH3-SiA) sense, 5'-GGUGAGACUGGAUCAUCAU-3' and anti-sense, 5'-UGAGUAAGUAUGUCGAGGC-3'; and si-GOLPH3-B (GOLPH3-SiB) sense, 5'-GACGCCGCAUCAAAGAAA-3' and anti-sense, 5'-UUUUUGAACUGAGGCGCUGCC-3'.

Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) was used for transfection. A total of 1 day before transfection, 3.5x10^4 cells were plated in a 6-well plate, such that they were 60-70% confluent at the time of transfection. Then, 30nm of the specific siRNA and 5 µl Lipofectamine 2000 reagent was mixed with 250 µl Opti-MEM (Gibco; Thermo Fisher Scientific, Inc.), and left to stand for 5 min. The diluted siRNA and Lipofectamine 2000 reagent were combined and incubated for another 20 min. Subsequently, the mixture was added to the cells. All siRNA silencing experiments were performed three times independently. siNC was used as the control group.

Additionally, treatment with Lipofectamine 2000 alone, under equivalent culture conditions, was used as a blank control group (Mock). All transfections lasted for 6 h in a humidified incubator with 5% CO2 at 37˚C. Then, 48 h after transfection, subsequent experimentation was performed.

GOLPH3 was overexpressed using a GOLPH3 pcDNA-3xFlag-C plasmid (Guangzhou RiboBio Co., Ltd.). An empty plasmid (3xFlag) was used as the negative control group. Treatment with Lipofectamine 2000 alone, under equivalent culture conditions, was used as a blank control group (Mock). The transfection protocol of the overexpression plasmid was similar to that of the siRNA, except that 2 µg plasmid was used for overexpression.

For co-transfections, cells were divided into the following five groups: i) GOLPH3 + NLRP3-SiNC group, GOLPH3 pcDNA-3xFlag-C plasmid and si-NC; ii) GOLPH3 + NLRP3-SiR group, GOLPH3 plasmid and si-NLRP3; iii) 3xFlag + NLRP3-SiR group, empty plasmid (3xFlag) and si-NLRP3; iv) 3xFlag + NLRP3-SiNC group (negative control), empty plasmid (3xFlag) and siNC; and v) mock group (blank control), treatment with Lipofectamine 2000 alone under equivalent culture conditions. The transfection protocol of the co-transfection was similar to that of the siRNA and the overexpression plasmid, except that 1 µg plasmid was used for co-transfection.

EdU incorporation assay. Transfected cells were seeded into 96-well plates at 5x10^4 cells per well and incubated for 24 h. When the confluency reached 60-70%, transfection was performed as described above. After 48 h, the cells were cultured in EdU medium for 2 h (Guangzhou RiboBio Co., Ltd.). Then, the cells were fixed with 4% paraformaldehyde for 30 min at room temperature, and treated with 0.5% Triton X-100 for 10 min at room temperature. After washing with PBS for 5 min with constant shaking, the cells were treated with 100 µl 1X Apollo® reaction cocktail (Guangzhou RiboBio Co., Ltd.) for 30 min. The DNA content of cells was stained with 100 µl of Hoechst 33342 (5 µg/ml) for another 30 min at room temperature. The results were observed under a fluorescence microscope (magnification, x200, Olympus DP80; Olympus Corporation).

Cell viability assay. Cell viability was measured using a Cell Counting Kit-8 (CCK-8) assay (Dojindo Molecular Technologies, Inc.) three times independently. Cells (3.5x10^4) were plated in a 96-well plate and cultured for 24 h, at 50-60% confluence at the time of transfection, and then transfected with siRNA or plasmid for 48 h. A total of 10 µl CCK-8 solution was added to each well and incubated for another 2 h. The absorbance at 450 nm (OD450) was measured using a microplate reader (Autobio Diagnostics Co., Ltd.).

Western blotting. The cells were lysed in RIPA lysis buffer (Beijing Solarbio Science & Technology Co., Ltd.) for 20 min on ice and collected using a cell scraper (Corning, Inc.). The total protein concentration was determined using a BCA Protein assay kit (Beijing Solarbio Science & Technology Co., Ltd.). Equivalent amounts of protein (40 µg) were loaded per lane to a 10% gel, resolved via SDS-PAGE, and subsequently transferred to a PVDF membrane. The membrane was blocked using 3% BSA (Beijing Solarbio Science & Technology Co., Ltd.) or
5% skimmed milk in TBS with 0.05% Tween-20 (TBST) for 1 h with constant shaking at room temperature. The membranes were incubated with antibodies against GOLPH3 (1:2,000; cat. no. ab98023; Abcam), NLRP3 (1:1,000; cat. no. ab263899; Abcam), Caspase-1/1P10 (1:1,000; cat. no. 22915-1-AP; ProteinTech Group, Inc.), IL-1β (1:1,000; cat. no. ab9722; Abcam), IxB (1:1,000; cat. no. ab76429; Abcam), phosphorylated (p)-IxB (1:10,000; cat. no. ab133462; Abcam) and β-actin (1:5,000; cat. no. 66009-1-lg; ProteinTech Group, Inc.) at 4°C overnight, and then incubated with horseradish peroxidase (HRP)-conjugated goat anti-mouse (cat. no. SA00001‑1) and goat anti-rabbit (cat. no. SA00001‑2) secondary antibodies (all at 1:10,000; ProteinTech Group, Inc.) for 1 h at room temperature after washing with TBST. The bands were visualized using a chemiluminescence detection kit (EMD Millipore) and densitometry was performed using ImageJ version 1.8.0.112 (National Institutes of Health). The relative amount of protein was normalized by dividing the density value of the target protein by the density value of the internal loading control.

**Immunohistochemistry**

**Specimen acquisition.** Pathological sections of gallbladders that had previously been paraffin-embedded pathological sections from 25 patients with GBC that underwent radical resection of GBC (GBC group) between January 2016 and January 2018 at the 904th Hospital of Joint Logistic Support Force of PLA (Wuxi, China), as well as 10 patients with gallstones who underwent laparoscopic cholecystectomy during the same period (control group) were obtained. Patients with GBC were diagnosed with T1-3 gallbladder adenocarcinoma by preoperative imaging, intraoperative exploration and postoperative pathology, and there was no evidence of distant metastases in any of the cases. The histopathology of the gallbladder in patients with gallstones after surgery suggested cholecystitis. All specimens were provided by the Department of Pathology, The 904th Hospital of Joint Logistic Support Force of PLA (25 gallbladder adenocarcinoma tissues, 10 gallbladder tissues with cholecystitis). Written informed consent was obtained from all patients and the study was approved by the Ethics Committee of the 904th Hospital of Joint Logistic Support Force of PLA (approval no. 2019-10-006).

**Tissue staining.** Tissue staining was performed using an immunohistochemical S-P kit (OriGene Technologies, Inc.), according to the manufacturer's protocol. Briefly, 4% paraformaldehyde was used for fixation at 4°C for 24 h. 5% BSA (Beijing Solarbio Science & Technology Co., Ltd.) was used to block non-specific sites for 30 min at 37°C. 3% hydrogen peroxide was used to block endogenous peroxidase activity at room temperature for 10 min to reduce non-specific background staining. The 4-µm sections were incubated with GOLPH3 (1:100; cat. no. 19112-1-AP; ProteinTech Group, Inc.), NLRP3 (1:50; cat. no. 19771-1-AP; ProteinTech Group, Inc.) or Ki-67 antibodies (1:5,000; cat. no. 27309-1-AP; ProteinTech Group, Inc.) with PBS as the blank control group) for 2 h at 37°C, followed by incubation with biotin-conjugated goat anti-rabbit IgG antibody (1:200; cat. no. TA130016; OriGene Technologies, Inc.) for 1 h at room temperature. Then, sections were reacted with 3, 3’-diaminobenzidine chromogenic reagent. The sections were counterstained with hematoxylin at room temperature for 30 sec and dehydrated in 100% xylene and finally sealed with neutral glue. The results were observed under an Olympus CX23 inverted microscope (Olympus Corporation).

**Evaluation.** The results of immunohistochemistry were analyzed using semi-quantitative integration (32). Randomly, five fields of view were selected for each slice (magnification, x200), and two pathologists assessed the degree of staining. Staining intensity (SI) was scored as follows: i) 0 points, undyed; ii) 1 point, lightly dyed or light yellow; iii) 2 points, yellow; and iv) 3 points, darkly dyed, brown or tan. The percentage of positively stained cells (PP) was scored as follows: i) 0 points, no staining; ii) 1 point, ≤10% of cells stained; iii) 2 points, 11-50% of cells stained; iv) 3 points, 51-80% of cells stained; and v) 4 points, >80% of cells stained. The final score was the product of the SI and the PP score: 0-3 points, negative (-) and >3 points, positive (+).

**Patients.** The clinical data of the 35 patients (25 GBC cases, 10 gallstone cases) were collected. The 25 patients with GBC (GBC group) all underwent R0 resection, including 10 male patients and 15 female patients, with a median age of 65.0 years (range, 36-85 years). The tumor staging was evaluated according to the 8th Edition of the AJCC TNM staging system (33); amongst the patients with GBC, seven cases were T1 stage, eight cases were T2 stage and 10 cases were T3 stage. In addition, 10 cases were accompanied by lymph node metastasis, none of which had distant metastases. The median survival of patients with GBC in the cohort was 19 months, and the 1, 3 and 5-year survival rates of the patients were 72, 24 and 12%, respectively. Amongst the 10 patients with gallstones (Control), four were men and six were women, with a median age of 65.5 years (range, 50-74 years). There was no significant difference in the sex or age between the GBC and control groups (P>0.05). None of patients had received any targeted antitumor treatments before surgery, such as chemotherapy, radiotherapy or targeted therapy.

**Surgery.** All patients with GBC underwent radical resection of GBC, and postoperative pathology confirmed R0 resection. Radical resection included cholecystectomy, partial hepatectomy, or regional lymph node dissection (hepatoduodenal ligament + posterior pancreas + aortic root). The scope of surgical resection was based on the tumor stage, and whether the extrahepatic bile duct was removed was determined according to the degree of invasion of the bile duct. All patients with cholelithiasis underwent laparoscopic cholecystectomy.

**Follow-up.** After the operation, patients with GBC were regularly followed up through clinics and telephone calls. In the first year, the patients were followed up every 3 months, every 6 months in the second year, and every 12 months in the third year. The follow-up was performed until 30 September 2020. The time between surgery and death or the end of follow-up was considered the overall survival.

**Statistical analysis.** All data were analyzed using SPSS version 23 (IBM Corp.), and the experiments were repeated at least three times. Quantitative data were analyzed using an unpaired Student's t-test or a Mann-Whitney U test, and
are expressed as the mean ± standard deviation, or the median (interquartile range), respectively. Qualitative data were analyzed using a χ² test or a Fisher's exact test. The Kaplan-Meier method was used for survival analysis. The Log-rank test was used to analyze the Kaplan-Meier curves. Pearson's linear correlation analysis was used to assess correlations. P<0.05 was considered to indicate a statistically significant difference.

Results

GOLPH3 and NLRP3 expression is upregulated in human GBC tissues and its expression is associated with Ki-67. First, the clinical relevance of GOLPH3 and NLRP3, as well as their relationship in clinical GBC samples were evaluated. The expression of GOLPH3, NLRP3 and the proliferative marker Ki-67 (34) in the gallbladder tissues of the 25 patients with GBC
and 10 patients with gallstones were assessed using immunohistochemical staining (Fig. 1). As shown in Fig. 1A and B, the percentage of GOLPH3- and NLRP3-positive cells in the gallbladder tissue of GBC cases was 4-5 times higher than that of the non-cancer tissues (GOLPH3 GBC, 43.2±27.1% and Control, 8.8±11.1%; NLRP3 GBC, 40.2±29.0% and Control, 5.9±8.7%), and the proportion of patients with GOLPH3- and NLRP3-positive expression in the GBC cases was significantly higher than that in the patients with gallstones (Table I). In addition, the percentage of GOLPH3-positive cells was positively correlated with the percentage of NLRP3-positive cells in GBC tissues (Fig. 1C). Additionally, the percentage of GOLPH3- and NLRP3-positive cells were both positively correlated with the percentage of Ki-67-positive cells in the GBC tissues (Fig. 1D). The results of the immunohistochemistry experiments also showed a similar trend (Fig. 1A).

Expression of GOLPH3 and NLRP3 is associated with a poor prognosis in patients with GBC. To explore the clinical significance of GOLPH3 and NLRP3, the clinicopathological data of the 25 patients with GBC was analyzed. The results showed that there was no significant difference in the age or sex of the GOLPH3- or NLRP3-positive and negative patients (Table II). However, the survival of GOLPH3-positive patients (16/25) or NLRP3-positive patients (15/25) was worse than the patients with negative expression (GOLPH3, median 16 vs. 55 months, P=0.001; NLRP3, median 16 vs. 40 months, P<0.001; Fig. 2A and B). Next, the relationship between the positive expression of GOLPH3 or NLRP3 and the clinicopathological characteristics of patients with GBC was assessed. The results suggested that GOLPH3- or NLRP3-positive patients had more advanced tumors (the TNM stage), deeper infiltration, poorly differentiated tumors and higher carbohydrate antigen 19-9 (CA199) or C-reactive protein (CRP) levels (Table II).

GOLPH3 promotes the proliferation of human GBC cells. To explore the possible role of GOLPH3 in the development of human GBC, GOLPH3-specific siRNAs were used to knock down the expression of GOLPH3 in GBC-SD cells. As shown in Fig. 3A and B, compared with the GOLDPH3-SiNC group, the protein expression levels of GOLPH3 decreased by 55-65% in the GBC-SD cells transfected with GOLDPH3-SiA and -SiB. Next, cell proliferation after GOLPH3 knockdown was evaluated using EdU and cell viability was evaluated using CCK-8 assays. The results of the EdU assay showed that the EdU-positive cells of the GOLPH3-SiA and -SiB groups were reduced by 40-80% compared with the GOLDPH3-SiNC group (Fig. 3C and D). Additionally, the results of the CCK-8 assay indicated that the OD450 in the GOLPH3-SiA and -SiB groups decreased by 20-30% compared with the GOLDPH3-SiNC group (Fig. 3E).

Next, GOLPH3 was overexpressed in GBC-SD cells, and the change in the proliferation of GBC cells was assessed. The results of western blotting showed that the GOLPH3-overexpression plasmid (Fig. 4F) was successfully transfected (Fig. 4A and B). The EdU assay showed that when GOLPH3 was overexpressed, the percentage of EdU positive cells increased by 30% compared with the 3xFlag group (Fig. 4C and D). In addition, the results of the CCK-8 assay suggested that the absorbance at 450 nm of the

| Group          | n   | Negative, n (%) | Positive, n (%) | Negative, n (%) | Positive, n (%) |
|----------------|-----|-----------------|-----------------|-----------------|-----------------|
| GBC            | 25  | 9 (36.0)        | 16 (64.0)       | 10 (40.0)       | 15 (60.0)       |
| Gallstones     | 10  | 8 (80.0)        | 2 (20.0)        | 9 (90.0)        | 1 (10.0)        |
| P-value        |     | 0.027           |                 | 0.010           |                 |

GOLPH3, Golgi phosphoprotein 3; GBC, gallbladder cancer; NLRP3, nucleotide-binding domain leucine-rich repeat and pyrin domain containing receptor 3.
Table II. Clinicopathological characteristics of the 25 patients with GBC.

### A, GOLPH3 expression

| Variable                                | Negative | Positive | $\chi^2$ | P-value |
|-----------------------------------------|----------|----------|----------|---------|
| Sex, n (%)                              |          |          |          |         |
| Male                                    | 4 (44.4) | 6 (37.5) | 0.000    | 1.000   |
| Female                                  | 5 (55.6) | 10 (62.5)|          |         |
| With gallstones, n (%)                  |          |          |          |         |
| Yes                                     | 7 (77.8) | 14 (87.5)| 0.405    | 0.602   |
| No                                      | 2 (22.2) | 2 (12.5) |          |         |
| With hypertension, n (%)                |          |          |          |         |
| Yes                                     | 5 (55.6) | 6 (37.5) | 0.762    | 0.434   |
| No                                      | 4 (44.4) | 10 (62.5)|          |         |
| Bile duct invasion, n (%)               |          |          |          |         |
| Yes                                     | 3 (33.3) | 5 (31.3) | 0.011    | 0.915   |
| No                                      | 6 (66.7) | 11 (68.8)|          |         |
| Infiltration depth, n (%)               |          |          | 4.890    | 0.040*  |
| T1+T2                                   | 8 (88.9) | 7 (43.8) |          |         |
| T3                                      | 1 (11.1) | 9 (56.3) |          |         |
| Lymph node metastasis, n (%)            |          |          | 1.852    | 0.229   |
| Yes                                     | 2 (22.2) | 8 (50.0) |          |         |
| No                                      | 7 (77.8) | 8 (50.0) |          |         |
| Differentiation, n (%)                  |          |          | 7.677    | 0.012*  |
| Poor                                    | 4 (44.4) | 15 (93.8)|          |         |
| High/medium                             | 5 (55.6) | 1 (6.3)  |          |         |
| TNM stage, n (%)                        |          |          | 6.173    | 0.033*  |
| I+II                                    | 8 (88.9) | 6 (37.5) |          |         |
| III                                     | 1 (11.1) | 10 (62.5)|          |         |
| Chemotherapy*, n (%)                    |          |          | 0.043    | 0.835   |
| Yes                                     | 3 (33.3) | 6 (37.5) |          |         |
| No                                      | 6 (66.7) | 10 (62.5)|          |         |
| Age, years, mean ± SD                   | 63.89±7.47 | 64.63±12.94 | -0.156c | 0.878   |
| White blood cells (x10^9/l), mean ± SD | 6.40±1.58 | 6.37±1.40  | 0.061c  | 0.951   |
| Total bilirubin, µmol/l, median (interquartile range) | 14.20 (10.20, 19.05) | 21.65 (12.00, 139.68) | 94.000d | 0.229   |
| CRP, g/l, median (interquartile range)  | 1.80 (0.95, 3.20) | 5.25 (2.90, 16.70) | 121.000d | 0.004*  |
| CEA, µg/l, median (interquartile range) | 1.97 (1.68, 4.01) | 2.12 (1.56, 5.82) | 72.000d  | 1.000   |
| CA199, U/ml, median (interquartile range) | 10.99 (9.71, 26.32) | 71.74 (20.98, 423.59) | 108.000d | 0.043*  |

### B, NLRP3 expression

| Variable                                | Negative | Positive | $\chi^2$ | P-value |
|-----------------------------------------|----------|----------|----------|---------|
| Sex, n (%)                              |          |          | 0.000    | 1.000   |
| Male                                    | 4 (40.0) | 6 (40.0) |          |         |
| Female                                  | 6 (60.0) | 9 (60.0) |          |         |
| With gallstones, n (%)                  |          |          | 0.000    | 1.000   |
| Yes                                     | 8 (80.0) | 13 (86.7)|          |         |
| No                                      | 2 (20.0) | 2 (13.3) |          |         |
| With hypertension, n (%)                |          |          | 0.244    | 0.697   |
| Yes                                     | 5 (50.0) | 6 (40.0) |          |         |
| No                                      | 5 (50.0) | 9 (60.0) |          |         |
| Bile duct invasion, n (%)               |          |          | 0.031    | 0.861   |
| Yes                                     | 3 (30.0) | 5 (33.3) |          |         |
| No                                      | 7 (70.0) | 10 (66.7)|          |         |
GOLPH3-overexpressing cells increased by 50% compared with the 3xFlag group (Fig. 4E). In summary, GOLPH3 overexpression promoted the proliferation of GBC cells.

**GOLPH3 regulates the NLRP3/Caspase-1 pathway.** It has been reported that GOLPH3 is related to PtdIns(4)p and the mTOR pathway, and that PtdIns(4)p is an important trigger for NLRP3 activation (21). There is also evidence showing that overexpression of mTOR can upregulate the levels of NLRP3 (30). Therefore, whether GOLPH3 could regulate NLRP3 was next assessed. Following knockdown or overexpression of GOLPH3, the protein expression levels of NLRP3 were determined by western blotting. As shown in Fig. 5A and B, the expression levels of NLRP3 in the cells transfected with GOLPH3-SiA and -SiB were significantly reduced, and significantly increased in the GOLPH3-overexpressing cells, suggesting that GOLPH3 could indeed regulate NLRP3. NLRP3 was knocked down in GBC-SD cells using siRNA, and proof of transfection was determined via western blotting (Fig. 5C). The expression levels of GOLPH3 were not significantly altered following knockdown of NLRP3 in GBC-SD cells (Fig. 5D), suggesting that NLRP3 may be located downstream of GOLPH3.

Whether GOLPH3 could activate Caspase-1 was next determined. The results of western blotting showed that overexpression of GOLPH3 increased Caspase-1 P10 levels, whereas knockdown of GOLPH3 reduced Caspase-1 P10 levels (Fig. 5A and B). Additionally, IL-1β and p-IκB, members of the NF-κB signaling pathway, showed similar trends to NLRP3 in the experiments (Fig. 5A and B). These results suggested that GOLPH3 could activate Caspase-1 through regulating NLRP3, and may have promoted the proliferation of GBC via the IL-1β and NF-κB pathway.

**GOLPH3 promotes GBC cell proliferation partially via regulation of NLRP3 in GBC-SD cells.** The aforementioned results indicated that GOLPH3 could increase the levels of NLRP3, as well as Caspase-1 activity, and GOLPH3 could also promote the proliferation of cells in GBC-SD. Thus, whether the effects of GOLPH3 on GBC cells were mediated via an NLRP3/Caspase-1 pathway were determined. The results of the EdU assay (Fig. 6C and D) showed that knockdown of NLRP3 alone inhibited the proliferation of GBC cells, and overexpression of GOLPH3 alone promoted it. However, in the GOLPH3 + NLRP3-SiR co-transfection group, the number of EdU-positive cells decreased, suggesting that the downregulation of NLRP3 partially offset cell proliferation caused by GOLPH3 overexpression in GBC-SD cells. The CCK-8 assays also showed similar results (Fig. 6E).
addition, the activation of Caspase-1 (pro-caspase-1/Caspase-1 P10) caused by GOLPH3 overexpression was partially abolished by knockdown of NLRP3, suggesting that the activation of Caspase-1 by GOLPH3 was also mediated by NLRP3 (Fig. 6A and B). Taken together, these results suggested that GOLPH3 promoted GBC cell proliferation, at least partially via a NLRP3/Caspase-1 pathway.

Discussion

In the present study, it was shown that GOLPH3 contributed to GBC progression via upregulation of NLRP3 expression, which resulted in the activation of Caspase-1, IL-1β and the NF-κB pathway. Additionally, GOLPH3, as well as NLRP3, were both associated with a poor prognosis in patients with GBC, which was supported by the following results. Firstly, knockdown of GOLPH3 inhibited GBC cell proliferation, whereas GOLPH3 overexpression promoted cell proliferation. Secondly, GOLPH3 regulated the protein expression levels of NLRP3 and the activation of Caspase-1, IL-1β, as well as the NF-κB pathway (p-IκB), whereas NLRP3 did not regulate GOLPH3. Thirdly, cell proliferation induced by overexpression of GOLPH3 was partially abolished by GOLPH3 knockdown. Additionally, GOLPH3 and NLRP3 were shown to be highly expressed in human GBC tissues, and there was a significant positive correlation between the expression of these two proteins, and both were positively correlated with the expression of Ki-67 in tissues. Finally, the survival of GOLPH3- or NLRP3-positive patients with GBC was worse than that of cases with negative expression, and GOLPH3 as well as NLRP3 positive expression were associated with the tumor stage, degree of differentiation, depth of invasion, and CA199 and CRP levels.

Several studies have reported that the activation of the NLRP3/Caspase-1 pathway is associated with tumor progression (24-27). Wang et al (25) found that when the NLRP3 inflammasome is activated, Caspase-1 is spliced to further activate the Akt, GSK-3p, ERK1/2 and CREB signaling pathways to promote tumor proliferation. The role of NLRP3 in cancer has gained increasing attention recently. However, the majority of previous studies have focused on investigating the downstream effectors of NLRP3. There has been no reports regarding the upstream effectors of NLRP3 in tumor progression to date, to the best of our knowledge. Conversely, although there is evidence showing that the TGN (21), PtdIns(4)p (21), mTOR (30) and PD2 (31) are closely related to the activation of NLRP3, these studies were all performed in macrophages. Whether this relationship also exists in tumor cells, and which proteins regulate these interactions remains unclear. In addition, several studies have reported that GOLPH3 is involved in the progression of various malignant tumors, such as lung cancer, pancreatic cancer, gastric cancer and brain glioma, via different signaling pathways, including the mTOR and FOXO1 pathway (6,11-14). However, the role of GOLPH3 in the progression of GBC is yet to be elucidated.
In the present study, GOLPH3 and NLRP3 were shown to be highly upregulated in clinical human GBC tissues, and there was a positive correlation between these two molecules, and both were also positively correlated with the expression of Ki-67 in the GBC tissues. Moreover, GOLPH3 promoted the proliferation of GBC cells and regulated the expression of NLRP3 as well as the activation of Caspase-1. However, NLRP3 did not affect GOLPH3 levels, indicating that GOLPH3 was located upstream of NLRP3. NLRP3 can activate Caspase-1, and further activate the Akt, GSK-3β, ERK1/2 and CREB pathways to promote adenocarcinoma proliferation (25). In the present study, it was shown that not
only NLRP3, but also GOLPH3 could promote the activation of Caspase-1, and this activation could be offset by knocking down NLRP3. Additionally, as IL-1β, an important member of NLRP3 inflammasome, has been reported to be associated with tumor proliferation, and the NF-κB signaling pathway is upstream of the inflammasome (21,25,28), the levels of IL-1β
and NF-κB pathway activation (based on p-IκB levels) were determined. The results showed that GOLPH3 could also regulate the protein expression levels of IL-1β and the activation of IκB, which indicated that GOLPH3 may promote the proliferation of GBC via IL-1β and the NF-κB pathway. Thus, GOLPH3 can also regulate the expression of NLRP3, further activate Caspase-1, IL-1β and the NF-κB pathway to promote the proliferation of gallbladder adenocarcinoma cells.

As for the exact mechanism by which GOLPH3 regulates NLRP3, this remains unknown. Based on the existing research, it is hypothesized that on the one hand, the excessive activation of GOLPH3 may cause the fragmentation of the TGN and break the binding of GOLPH3 and PtdIns(4)p. The free PtdIns(4)p then bind to NLRP3 and activates the entire inflammasome, further affecting the protein levels of NLRP3 (8,21). Additionally, GOLPH3 activates the mTOR molecular pathway, which further increases the levels of NLRP3 (30). However, due to a lack of direct and effective methods to detect the activation of NLRP3, only the levels of NLRP3 expression were assessed in the present study. It is unclear whether the effects of GOLPH3 on NLRP3 occur by affecting the activity of NLRP3, or by directly affecting the expression of NLRP3. It will be interesting to further reveal the underlying mechanism by which GOLPH3 regulates NLRP3.

In addition, through the analysis of patient clinical data, it was found that patients with positive expression of GOLPH3 or NLRP3 had worse overall survival compared with the negative patients, suggesting that this pathway also affects the overall survival of patients in vivo. Additionally, GOLPH3- and NLRP3-positive patients had less differentiated tumors, more advanced tumors, deeper infiltration and high levels of CA199, suggesting that the tumors in these patients were more aggressive compared with the negative patients. Of note, it was found that the expression of GOLPH3 and NLRP3 in vivo was associated with the levels of CRP in the peripheral blood, which further revealed the connection between this pathway and inflammation.

In conclusion, it was observed that GOLPH3 promoted the proliferation of GBC cells by regulating NLRP3 in vitro. Additionally, the positive correlation between the expression levels of these proteins was shown, and it was also shown that their expression was positively correlated with the expression of the proliferation marker Ki-67 in vivo. Patients with...
positive expression of GOLPH3 or NLRP3 tended to have worse overall survival, and the expression of both of these proteins was related to the patients’ tumor stage, degree of differentiation, depth of invasion, and CA199 and CRP levels. This research provided evidence regarding the existence of a GOLPH3-NLRP3-Caspase-1 signaling pathway in human GBC.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors’ contributions

KL contributed to the conception of the present study. ZZ prepared the manuscript and contributed to performing the experiments. KL and ZZ confirmed the authenticity of all the raw data. QZ analyzed the data and performed part of the experiments. DC assisted in completing part of the experiments. LC contributed to data collection. WX performed the follow-ups of patients in the present study. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Written informed consent was obtained from all patients and the study was approved by the Ethics Committee of the 904th Hospital of Joint Logistic Support Force of PLA (approval no. 2019-10-006; Wuxi, China).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Hundal R and Shaffer EA: Gallbladder cancer: Epidemiology and outcome. Clin Epidemiol 6: 99-109, 2014.
2. Gamboa AC and Maithel SK: The landmark series: Gallbladder cancer. Ann Surg Oncol 27: 2846-2858, 2020.
3. Song X, Hu Y, Li Y, Shao R, Liu F and Liu Y: Overview of current targeted therapy in gallbladder cancer. Signal Transduct Target Ther 5: 230, 2020.
4. Goetzte TO: Gallbladder carcinoma: Prognostic factors and therapeutic options. World J Gastroenterol 21: 12211-12217, 2015.
5. Kuma RS and Field SJ: GOLPH3: A Golgi phosphatidylinositol(4) phosphate effector that directs vesicle trafficking and drives cancer. J Lipid Res 60: 269-275, 2019.
6. Zou X, Xue P, Yang M, Shi H, Lu D, Wang Z, Shi Q, Hu J, Xie S, Zhan W and Yu R: Protein kinase D2 promotes the proliferation of glioma cells by regulating Golgi phosphoprotein 3. Cancer Lett 555: 121-129, 2021.
7. Sechi S, Frappalo A, Karimpour-Ghahnavieh A, Piergentili R and Giansanti MG: Oncogenic roles of GOLPH3 in the physiopathology of cancer. Int J Mol Sci 21: 933, 2020.
8. Farber-Katz SE, Dippold HC, Buchsman MD, Peterman MC, Xing M, Noakes CJ, Lat J, Ng MM, Rahajeng J, Cowan DM, et al: DNA damage triggers Golgi dispersal via DNA-PK and GOLPH3. Cell 156: 413-427, 2014.
9. Buschman MD, Xing M and Field SJ: The GOLPH3 pathway regulates Golgi shape and function and is activated by DNA damage. Front Neurosci 9: 362, 2015.
10. Bergeron JJM, Au CE, Thomas DY and Herro L: Proteinomes identifies Golgi phosphoprotein 3 (GOLPH3) with a link between Golgi structure, cancer, DNA damage and protection from cell death. Mol Cell Proteomics 16: 2048-2054, 2017.
11. Tang S, Pan H, Wei W, Yang H, Liu J and Yang R: GOLPH3: A novel biomarker that correlates with poor survival and resistance to chemotherapy in breast cancer. Oncotarget 8: 105155-105169, 2017.
12. Liu H, Wang X, Feng B, Tang L, Li W, Zheng X, Liu Y, Peng Y, Zheng G and He Q: Golgi phosphoprotein 3 (GOLPH3) promotes hepatocellular carcinoma progression by activating mTOR signalling pathway. BMC Cancer 18: 661, 2018.
13. Liu J, Wei H, Lai L, Wang Y, Han X and Zeng J: Golgi phosphoprotein-3 promotes invasiveness of gastric cancer cells through the mTOR signalling pathway. Clin Invest Med 42: E38-E47, 2019.
14. Zhao G, Zhang J, Ma L, Wu H, Zhang H, Su J, Geng B, Yao Q and Zheng J: GOLPH3 promotes angiogenesis of lung adenocarcinoma by regulating the Wnt/b-catenin signaling pathway. Onco Targets Ther 13: 6265-6277, 2020.
15. Zhang Q, Zhuang J, Deng Y, Yang L, Cao W, Chen W, Lin T, Lv X, Yu H, Xue Y and Guo H: miR34a/GOLPH3 axis abrogates uteroplacental bladder cancer chemoresistance via reduced cancer stemness. Theranostics 7: 4777-4790, 2017.
16. Yu T, An Q, Cao XL, Yang H, Cui J, Li ZJ and Xiao G: GOLPH3 inhibition reverses exapilatin resistance of colon cancer cells via suppression of PI3K/AKT/mTOR pathway. Life Sci 260: 118294, 2020.
17. Zeng Z, Lin H, Zhao X, Liu G, Wang X, Xu R, Chen K, Li J and Song L: Overexpression of GOLPH3 promotes proliferation and tumorigenicity in breast cancer via suppression of the FOXO1 transcription factor. Clin Cancer Res 18: 4059-4069, 2012.
18. Lim Y and Kumar S: A single cut to pyroptosis. Oncotarget 6: 36926-36927, 2015.
19. Islam MT, Bardaweel SK, Mubarak MS, Koch W, Gaweł-Beben K, Antosiewicz B and Sharifit-Rad J: Immunomodulatory effects of diterpenes and their derivatives through NLRP3 inflammasome pathway: A review. Front Immunol 11: 57916, 2020.
20. Latz E, Xiao TS and Stutz A: Activation and regulation of the NLRP3 inflammasome. Nat Rev Immunol 3: 2053‑2064, 2016.
21. Chen Z, He M, Chen J, Li C and Zhang Q: Long non-coding RNA SNHG7 inhibits NLRP3-dependent pyroptosis by targeting the miR-34a/SIRT1 axis in liver cancer. Oncol Lett 20: 893-901, 2020.
22. Feng YS, Tan ZX, Wu LY, Dong F and Zhang F: The involvement of NLRP3 inflammasome in the treatment of Alzheimer’s disease. Aging Res Rev 64: 101192, 2020.
23. Lu F, Zhao Y, Pang Y, Ji M, Sun Y, Wang H, Zou J, Wang Y, Li G, Sun T, et al: NLRP3 inflammasome upregulates PD-L1 expression and contributes to immune suppression in lymphoma. Cancer Lett 497: 178-189, 2021.
24. Tezcan G, Garanieva EE, Zhuravleva MN, Hamza S, Rizovan AA and Khaiboullina SF: Rab GTPase mediating regulation of NLRP3 inflammasome in the treatment of Alzheimer’s disease. Aging Res Rev 64: 101192, 2020.
25. Wang Y, Kong H, Zeng X, Liu W, Wang Z, Yan X, Wang H and Xie W: Activation of NLRP3 inflammasome enhances the proliferation and migration of A549 lung cancer cells. Oncol Lett 13: 2053-2064, 2016.
26. Chen Z, Liu Q, Zhu Z, Xiang F, Zhang M, Wu R and Kang X: Urosolic acid protects against proliferation and inflammatory response in LPS-Treated gastric tumour model and cells by inhibiting NLRP3 inflammasome activation. Cancer Manag Res 12: 8413-8424, 2020.
28. Guo R, Qin Y, Shi P, Xie J, Chou M and Chen Y: IL-1β promotes proliferation and migration of gallbladder cancer cells via Twist activation. Oncol Lett 12: 4749-4755, 2016.
29. Dippold HC, Ng MM, Farber-Katz SE, Lee SK, Kerr ML, Peterman MC, Sim R, Wharto PA, Galbraith KA, Madhavarapu S, et al: GOLPH3 bridges phosphatidylinositol-4-phosphate and actomyosin to stretch and shape the Golgi to promote budding. Cell 139: 337-351, 2009.
30. Li X, Zhang X, Pan Y, Shi G, Ren J, Fan H, Dou H and Hou Y: mTOR regulates NLRP3 inflammasome activation via reactive oxygen species in murine lupus. Acta Biochim Biophys Sin (Shanghai) 50: 888-896, 2018.
31. Zhang Z, Meszaros G, He WT, Xu Y, de Fatima Magliarello H, Mailly L, Mihlan M, Liu Y, Puig Gámez M, Goginashvili A, et al: Protein kinase D at the Golgi controls NLRP3 inflammasome activation. J Exp Med 214: 2671-2693, 2017.
32. Friedrichs K, Gluba S, Eidtmann H and Jonat W: Overexpression of p53 and prognosis in breast cancer. Cancer 72: 3641-3647, 1993.
33. Lamartina L, Grani G, Arvat E, Nervo A, Zatelli MC, Rossi R, Puxeddu E, Morelli S, Torlontano M, Massa M, et al: 8th edition of the AJCC/TNM staging system of thyroid cancer: What to expect (ITCO#2). Endocr Relat Cancer 25: L7-L11, 2018.
34. Hui AM, Shi YZ, Li X, Sun L, Guido T, Takayama T and Makuuchi M: Proliferative marker Ki-67 in gallbladder carcinomas: High expression level predicts early recurrence after surgical resection. Cancer Lett 176: 191-198, 2002.